These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35635854)

  • 1. Distinguishing placenta accreta from placenta previa via maternal plasma levels of sFlt-1 and PLGF and the sFlt-1/PLGF ratio.
    Zhang F; Gu M; Chen P; Wan S; Zhou Q; Lu Y; Li L
    Placenta; 2022 Jun; 124():48-54. PubMed ID: 35635854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum.
    Faraji A; Akbarzadeh-Jahromi M; Bahrami S; Gharamani S; Raeisi Shahraki H; Kasraeian M; Vafaei H; Zare M; Asadi N
    J Obstet Gynaecol; 2022 Jul; 42(5):900-905. PubMed ID: 34558384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa.
    Wang N; Shi D; Li N; Qi H
    Ann Med; 2021 Dec; 53(1):2041-2049. PubMed ID: 34927512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The correlation between serum levels and placental tissue expression of PLGF and sFLT-1 and the FIGO grading of the placenta accreta spectrum disorders.
    Alessandrini L; Aryananda R; Ariani G; Agustina B; Akbar MIA; Dachlan EG; Dekker G; Ernawati E
    J Matern Fetal Neonatal Med; 2023 Dec; 36(1):2183744. PubMed ID: 36859823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of circulating total sFLT-1 to placental-specific sFLT-1 e15a in women with suspected preeclampsia.
    Rowson S; Reddy M; De Guingand DL; Langston-Cox A; Marshall SA; da Silva Costa F; Palmer KR
    Placenta; 2022 Mar; 120():73-78. PubMed ID: 35227983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
    Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum angiogenic profile in abnormal placentation.
    Biberoglu E; Kirbas A; Daglar K; Biberoglu K; Timur H; Demirtas C; Karabulut E; Danisman N
    J Matern Fetal Neonatal Med; 2016 Oct; 29(19):3193-7. PubMed ID: 26863111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal serum sFlt-1/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies.
    Dröge L; Herraìz I; Zeisler H; Schlembach D; Stepan H; Küssel L; Henrich W; Galindo A; Verlohren S
    Ultrasound Obstet Gynecol; 2015 Mar; 45(3):286-93. PubMed ID: 25491901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy.
    Gurnadi JI; Mose J; Handono B; Satari MH; Anwar AD; Fauziah PN; Yogi Pramatirta A; Rihibiha DD
    BMC Res Notes; 2015 Oct; 8():534. PubMed ID: 26434493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of serum levels and placental bed tissue expression of IGF-1, bFGF, and PLGF in patients with placenta previa complicated with placenta accreta spectrum disorders.
    Arakaza A; Liu X; Zhu J; Zou L
    J Matern Fetal Neonatal Med; 2024 Dec; 37(1):2305264. PubMed ID: 38247274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
    Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
    Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total Versus Free Placental Growth Factor Levels in the Pathogenesis of Preeclampsia.
    Lecarpentier E; Zsengellér ZK; Salahuddin S; Covarrubias AE; Lo A; Haddad B; Thadhani RI; Karumanchi SA
    Hypertension; 2020 Sep; 76(3):875-883. PubMed ID: 32654553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1).
    Neuman RI; Baars MD; Saleh L; Broekhuizen M; Nieboer D; Cornette J; Schoenmakers S; Verhoeven M; Koch BCP; Russcher H; van den Berg SAA; van den Meiracker AH; Visser W; Danser AHJ
    Hypertension; 2022 Jun; 79(6):1297-1307. PubMed ID: 35341328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable?
    Stepan H; Hund M; Dilba P; Sillman J; Schlembach D
    Clin Chem Lab Med; 2019 Aug; 57(9):1339-1348. PubMed ID: 31323000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
    Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
    Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers of placental function correlate with prevalence and quantity of nucleated fetal cells in maternal circulation in normotensive term pregnancies.
    Fjeldstad HE; Jacobsen DP; Johnsen GM; Sugulle M; Chae A; Kanaan SB; Gammill HS; Staff AC
    Acta Obstet Gynecol Scand; 2023 Jun; 102(6):690-698. PubMed ID: 36933003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.
    Aminuddin NA; Sutan R; Mahdy ZA; Rahman RA; Nasuruddin DN
    PLoS One; 2022; 17(3):e0265080. PubMed ID: 35275947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast.
    Wehrum MJ; Buhimschi IA; Salafia C; Thung S; Bahtiyar MO; Werner EF; Campbell KH; Laky C; Sfakianaki AK; Zhao G; Funai EF; Buhimschi CS
    Am J Obstet Gynecol; 2011 May; 204(5):411.e1-411.e11. PubMed ID: 21316642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sFlt-1/PlGF ratio as a predictor for poor pregnancy and neonatal outcomes.
    Chang YS; Chen CN; Jeng SF; Su YN; Chen CY; Chou HC; Tsao PN; Hsieh WS
    Pediatr Neonatol; 2017 Dec; 58(6):529-533. PubMed ID: 28571908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.